Ciprofloxacin/Fluocinolone Shortage: What Providers and Prescribers Need to Know in 2026

If you've been prescribing ciprofloxacin/fluocinolone (Otovel) for pediatric AOMT, you've likely fielded calls from parents and caregivers unable to fill the prescription. The medication is not in a declared FDA shortage, but stocking gaps at retail pharmacies are a recurring practical challenge for patients and prescribers alike.

This guide is intended for otolaryngologists, pediatricians, family practitioners, nurse practitioners, and physician assistants who regularly prescribe otic therapies for AOMT. We'll review the current availability situation, evidence-based alternatives, prescribing considerations, and tools to help your patients succeed.

Current Availability Status: Not a Formal Shortage, But Persistently Difficult

As of 2026, ciprofloxacin/fluocinolone acetonide otic solution (Otovel) is not listed on the FDA Drug Shortages database maintained by CDER. The drug's manufacturer continues to produce it. However, several structural factors create consistent availability problems at the pharmacy level:

Narrow indication and low prescription volume: AOMT is a pediatric condition, and Otovel's sole approved indication is its treatment. Many retail pharmacies do not maintain standing inventory due to infrequent demand.

Specialty packaging: 14 individual sterile single-dose vials per foil pouch requires different handling than standard multi-dose otic bottles. This can complicate inventory management at standard retail pharmacies.

Cost and coverage barriers: Retail price of $361–$395 per course. Variable insurance coverage and potential prior authorization requirements create fill-rate pressure that reduces pharmacy stock levels.

Generic availability gaps: The generic (ciprofloxacin-fluocinolone acetonide PF) is available but also not universally stocked, and pharmacy awareness of it as a substitution option varies.

Evidence-Based Alternatives for AOMT in 2026

When ciprofloxacin/fluocinolone is unavailable, the following alternatives are supported by clinical evidence and are appropriate for AOMT management:

1. Ciprofloxacin/Dexamethasone (Ciprodex) — First-Line Alternative

Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension is the most evidence-supported alternative for AOMT. It is FDA-approved for AOMT in patients 6 months and older, covers the same pathogen spectrum (S. aureus, S. pneumoniae, H. influenzae, M. catarrhalis, P. aeruginosa), and is widely available as a generic at $30–$80 per course.

Key clinical distinction: Ciprodex contains benzalkonium chloride (a preservative) and is a suspension (requires shaking). Otovel is preservative-free and a clear solution in single-dose vials. For most AOMT cases, the clinical efficacy difference is not material.

2. Ofloxacin Otic Solution — Antibiotic Monotherapy Option

Ofloxacin 0.3% otic solution is FDA-approved for AOMT and appropriate when a steroid component is not needed or when the prescriber prefers antibiotic monotherapy. It is safe for use with tympanostomy tubes (no ototoxicity), widely available as a generic, and typically costs $10–$40.

Dosing for AOMT: 5 drops in the affected ear(s) twice daily for 10 days in patients 1 year and older with tympanostomy tubes.

What to Avoid: Aminoglycoside-Containing Drops

Aminoglycoside-containing preparations (e.g., neomycin in Cortisporin Otic) are ototoxic and should not be used in patients with non-intact tympanic membranes, including those with tympanostomy tubes. This is a critical distinction when selecting an alternative to Otovel.

Prescribing Strategies to Reduce Fill Failures

Consider these strategies to reduce the frequency of fill failures for your AOMT patients:

Write for both brand and generic. Indicate on the prescription: "Otovel (ciprofloxacin/fluocinolone acetonide 0.3%/0.025% otic solution) — generic acceptable (ciprofloxacin-fluocinolone acetonide PF)."

Provide a backup prescription. Consider giving parents a co-prescription for Ciprodex or ofloxacin otic in case the primary cannot be filled, with instructions to call the office before using the backup if there is any uncertainty.

Direct patients to children's hospital pharmacies. Pediatric specialty pharmacies routinely stock otic medications that many retail pharmacies do not.

Recommend medfinder to patients. medfinder calls pharmacies near the patient to check stock and texts results — especially useful for specialty medications like Otovel.

Insurance and Prior Authorization Considerations

Some commercial plans and Medicaid programs require step therapy for Otovel, requiring trial of a less expensive alternative (such as ofloxacin or generic Ciprodex) before covering it. If your patient needs Otovel specifically, be prepared to provide clinical documentation supporting the need for the combination antibiotic-steroid product and the single-dose vial format.

Patient Counseling Points

When prescribing ciprofloxacin/fluocinolone, counsel patients and caregivers on the following:

Warm each vial in the hand for 1–2 minutes before instillation to prevent dizziness from cold solution

Patient should lie with affected ear upward; pump tragus 4 times to facilitate penetration to the middle ear

Complete the full 7-day course even if symptoms resolve early

Return for evaluation if otorrhea persists after 7 days or recurs within 6 months (may indicate underlying pathology)

For additional resources for providers managing specialty prescriptions, visit medfinder for providers.